[go: up one dir, main page]

TN2009000224A1 - Inhibitors of akt activity - Google Patents

Inhibitors of akt activity

Info

Publication number
TN2009000224A1
TN2009000224A1 TNP2009000224A TN2009000224A TN2009000224A1 TN 2009000224 A1 TN2009000224 A1 TN 2009000224A1 TN P2009000224 A TNP2009000224 A TN P2009000224A TN 2009000224 A TN2009000224 A TN 2009000224A TN 2009000224 A1 TN2009000224 A1 TN 2009000224A1
Authority
TN
Tunisia
Prior art keywords
akt activity
inhibitors
compounds
akt
provides
Prior art date
Application number
TNP2009000224A
Other languages
English (en)
Inventor
Michael J Kelly Iii
Mark E Layton
Philip E Sanderson
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of TN2009000224A1 publication Critical patent/TN2009000224A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
TNP2009000224A 2006-12-06 2009-06-03 Inhibitors of akt activity TN2009000224A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87319806P 2006-12-06 2006-12-06
US88066107P 2007-01-16 2007-01-16
US96787207P 2007-09-06 2007-09-06
PCT/US2007/024772 WO2008070041A2 (fr) 2006-12-06 2007-12-03 Inhibiteurs de l'activité akt

Publications (1)

Publication Number Publication Date
TN2009000224A1 true TN2009000224A1 (en) 2010-10-18

Family

ID=39492823

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000224A TN2009000224A1 (en) 2006-12-06 2009-06-03 Inhibitors of akt activity

Country Status (29)

Country Link
US (3) US7576209B2 (fr)
EP (1) EP2104669B1 (fr)
JP (2) JP4431636B1 (fr)
KR (1) KR101110598B1 (fr)
CN (1) CN101600706B (fr)
AR (1) AR064010A1 (fr)
AU (1) AU2007328286B2 (fr)
BR (1) BRPI0719580A2 (fr)
CA (1) CA2670760C (fr)
CL (1) CL2007003495A1 (fr)
CO (1) CO6190528A2 (fr)
CR (1) CR10851A (fr)
EA (1) EA016195B1 (fr)
EC (1) ECSP099376A (fr)
ES (1) ES2527567T3 (fr)
GE (1) GEP20125469B (fr)
GT (1) GT200900146A (fr)
HN (1) HN2009001112A (fr)
IL (2) IL198826A (fr)
MA (1) MA31027B1 (fr)
MX (1) MX2009006052A (fr)
NI (1) NI200900106A (fr)
NO (1) NO20092569L (fr)
NZ (2) NZ595829A (fr)
PE (1) PE20081341A1 (fr)
SV (1) SV2009003283A (fr)
TN (1) TN2009000224A1 (fr)
TW (1) TWI386410B (fr)
WO (2) WO2008070016A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015578A (es) * 2005-06-10 2008-03-06 Merck & Co Inc Inhibidores de la actividad akt.
EP2120951A4 (fr) * 2006-12-06 2012-02-15 Merck Sharp & Dohme Inhibiteurs de l'activité akt
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
AU2009255358A1 (en) * 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
EP2299825B1 (fr) * 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
WO2010002010A1 (fr) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Nouveaux acides spirochromanone carboxyliques
EP2328871B1 (fr) * 2008-08-25 2020-04-01 Novartis AG Modulateurs de la voie hedgehog
DE102008043724A1 (de) * 2008-11-13 2010-05-20 Biotronik Vi Patent Ag Erhöhung der Effizienz pharmazeutische Wirkstoffe-freisetzender Medizinprodukte durch Kombination mit einem Inhibitor des Transportproteins P-Glycoprotein
AU2010208480A1 (en) * 2009-02-02 2011-07-28 Msd K.K. Inhibitors of Akt activity
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010101734A1 (fr) 2009-03-06 2010-09-10 Merck Sharp & Dohme Corp. Thérapie de combinaison anti-cancer avec un inhibiteur de akt et d'autres agents anti-cancer
WO2010104705A1 (fr) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
EP2475659B1 (fr) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag Composés de pyridin-3-yl-carboxamide 4-substitué et procédés d'utilisation
US8546376B2 (en) 2009-09-18 2013-10-01 Almac Discovery Limited Pharmaceutical compounds
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
WO2011130921A1 (fr) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité d'akt
EP2572199B1 (fr) 2010-05-21 2017-03-08 Novartis AG Combinaison
CA2804845A1 (fr) 2010-07-12 2012-01-19 Stuart Ince Imidazo[1,2-a]pyrimidines et -pyridines substitues
EP2593458A1 (fr) 2010-07-13 2013-05-22 Bayer Intellectual Property GmbH Pyrimidines bicycliques
CN103384670B (zh) 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
EP2651949B1 (fr) * 2010-12-16 2015-07-15 Bayer Intellectual Property GmbH Pyrimido [1,2-b]indazoles substitués et leur utilisation comme modulateurs de la voie pi3k/akt
SG10201600077RA (en) * 2011-01-11 2016-02-26 Glaxosmithkline Llc Combination
WO2012137870A1 (fr) 2011-04-06 2012-10-11 大鵬薬品工業株式会社 Nouvelle imidazo-oxazine ou l'un de ses sels
PL2694510T3 (pl) 2011-04-07 2016-03-31 Bayer Ip Gmbh Imidazopirydazyny jako inhibitory kinazy Akt
WO2012177844A2 (fr) 2011-06-24 2012-12-27 Arqule, Inc. Composés d'imidazopyridinyle-aminopyridine substitués
WO2012177852A1 (fr) * 2011-06-24 2012-12-27 Arqule, Inc Composés d'imidazopyridinyle substitués
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2802588B1 (fr) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Pyrazolopyrimidines substituées comme inhibiteurs de kinase akt
EP2802586B1 (fr) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Imidazopyrazines substituées comme inhibiteurs de kinase akt
EP2804616B1 (fr) 2012-01-20 2018-07-18 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Contrôle glycémique amélioré utilisant un inhibiteur d'ad36e4orf1 et d'akt1
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
AU2013284570B2 (en) 2012-07-02 2016-04-14 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator composed of imidazooxazine compound
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
EP3033088A4 (fr) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarqueurs pour le traitement de troubles néoplasiques à l'aide de thérapies ciblant les androgènes
BR112016006970A2 (pt) 2013-10-01 2017-08-01 Novartis Ag enzalutamida em combinação com afuresertib para o tratamento de câncer
CN109674801A (zh) 2013-10-01 2019-04-26 诺华股份有限公司 组合
WO2015094928A1 (fr) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Compositions liposomales pour inhibiteurs akt allostériques
IL311537A (en) 2014-01-28 2024-05-01 Mayo Found Medical Education & Res Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging
CA2942204A1 (fr) 2014-03-12 2015-09-17 Novartis Ag Combinaison comprenant un inhibiteur de btk et un inhibiteur d'atk
EP3119395B1 (fr) * 2014-03-17 2021-04-28 Merck Sharp & Dohme Corp. Nanoparticules polymères et leurs procédés de fabrication et d'utilisation
WO2016136928A1 (fr) 2015-02-27 2016-09-01 大鵬薬品工業株式会社 Cristal d'imidazo-oxazine, composition pharmaceutique contenant ledit cristal, et procédé de production dudit cristal
FR3033499A1 (fr) 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
EP3372601B1 (fr) * 2015-10-22 2022-09-21 Mitsubishi Tanabe Pharma Corporation Nouveau composé hétérocyclique bicyclique
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2017156350A1 (fr) 2016-03-09 2017-09-14 K-Gen, Inc. Méthodes de traitement du cancer
CN108426971B (zh) * 2018-03-09 2020-03-20 浙江中一检测研究院股份有限公司 一种快速检测水中微囊藻毒素的方法
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
EP4073102A4 (fr) 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions et méthodes de prévention et de traitement de la perte d'audition
AU2021269065A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators and methods of use thereof
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2023092094A2 (fr) 2021-11-19 2023-05-25 The Broad Institute, Inc. Molécules chimériques bifonctionnelles pour le marquage de kinases avec des fractions de liaison cibles et leurs méthodes d'utilisation
EP4604957A1 (fr) 2022-10-17 2025-08-27 Astrazeneca AB Combinaisons d'un serd pour le traitement du cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002252614B2 (en) 2001-04-10 2006-09-14 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2442264A1 (fr) * 2001-04-10 2002-10-24 Merck & Co., Inc. Methode de traitement du cancer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003086394A1 (fr) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibiteurs de l'activite akt
AU2003226271B2 (en) 2002-04-08 2007-10-18 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of Akt activity
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
CA2481229C (fr) 2002-04-08 2010-09-21 Merck & Co., Inc. Pyrazines substituees inhibitrices de l'akt
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
AU2004233827B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE602004023838D1 (de) 2003-04-24 2009-12-10 Merck & Co Inc Hemmer der akt aktivität
EP1622616B1 (fr) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibiteurs de l'activite akt
CA2522262A1 (fr) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibiteurs de l'activite de l'akt
WO2005007099A2 (fr) 2003-07-10 2005-01-27 Imclone Systems Incorporated Inhibiteurs de la pkb utilises comme agents antitumoraux
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
JP4110324B2 (ja) * 2003-10-15 2008-07-02 宇部興産株式会社 新規インダゾール誘導体
ATE499364T1 (de) 2004-04-09 2011-03-15 Merck Sharp & Dohme Hemmer der akt aktivität
JP2007532551A (ja) 2004-04-09 2007-11-15 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
JP2008521917A (ja) * 2004-12-02 2008-06-26 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性のインヒビター
AU2005316826A1 (en) 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2597456A1 (fr) 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibiteurs d'activite d'akt
WO2006110638A2 (fr) * 2005-04-12 2006-10-19 Merck & Co., Inc. Inhibiteur de l'activite akt
MX2007015578A (es) 2005-06-10 2008-03-06 Merck & Co Inc Inhibidores de la actividad akt.
EP1978966A4 (fr) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc Inhibiteurs tricycliques de la 5-lipoxygenase
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP5516397B2 (ja) * 2007-04-05 2014-06-11 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法

Also Published As

Publication number Publication date
CN101600706A (zh) 2009-12-09
CR10851A (es) 2009-06-25
CA2670760A1 (fr) 2008-06-12
AU2007328286B2 (en) 2011-01-20
NI200900106A (es) 2010-01-20
WO2008070041A2 (fr) 2008-06-12
US20080161317A1 (en) 2008-07-03
ECSP099376A (es) 2009-07-31
CA2670760C (fr) 2012-01-24
JP2010511703A (ja) 2010-04-15
IL205220A0 (en) 2011-07-31
EP2104669A2 (fr) 2009-09-30
KR20090086095A (ko) 2009-08-10
JP2009298786A (ja) 2009-12-24
AR064010A1 (es) 2009-03-04
NZ595829A (en) 2013-04-26
WO2008070016A2 (fr) 2008-06-12
HN2009001112A (es) 2011-07-22
MX2009006052A (es) 2009-06-17
AU2007328286A1 (en) 2008-06-12
JP4431636B1 (ja) 2010-03-17
US8288407B2 (en) 2012-10-16
NO20092569L (no) 2009-07-06
AU2007328286A2 (en) 2009-08-06
HK1137758A1 (en) 2010-08-06
GEP20125469B (en) 2012-04-10
PE20081341A1 (es) 2008-10-19
TW200831509A (en) 2008-08-01
NZ577470A (en) 2011-11-25
BRPI0719580A2 (pt) 2013-12-17
TWI386410B (zh) 2013-02-21
ES2527567T3 (es) 2015-01-26
EP2104669B1 (fr) 2014-10-15
WO2008070041A3 (fr) 2008-08-28
MA31027B1 (fr) 2009-12-01
GT200900146A (es) 2010-04-13
SV2009003283A (es) 2009-11-09
US20110160183A1 (en) 2011-06-30
WO2008070016A3 (fr) 2008-09-12
CL2007003495A1 (es) 2008-05-30
JP5364454B2 (ja) 2013-12-11
IL198826A (en) 2010-11-30
CN101600706B (zh) 2013-10-16
EA016195B1 (ru) 2012-03-30
KR101110598B1 (ko) 2012-03-08
CO6190528A2 (es) 2010-08-19
US20090253734A1 (en) 2009-10-08
EA200970542A1 (ru) 2009-12-30
US7576209B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
TN2009000224A1 (en) Inhibitors of akt activity
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
WO2008030883A3 (fr) Traitement du cancer
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
WO2006135604A3 (fr) Inhibiteurs de kinases checkpoint
SG164368A1 (en) Treatment of cancer
MX2010001565A (es) Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90.
MX2009008547A (es) Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer.
MY153243A (en) Compound for inhibiting mitotic progression
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2006106326A8 (fr) Heterocycles substitues et leur utilisation en tant qu’inhibiteurs de la chk1, de la pdk1 et de la pak
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2007059154A3 (fr) Traitement de cancers a resistance acquise a des inhibiteurs de kit
WO2006068796A3 (fr) Inhibiteurs de l'activite de akt
MX2009008073A (es) Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados.
WO2007008502A3 (fr) Inhibiteurs de kinases 'points de controle'
WO2007084135A3 (fr) Inhibiteurs des kinases du point de controle
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
WO2007081572A3 (fr) Inhibiteurs de kinases point de controle